Can Wang
Harbin, 150000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Disrupting fumarylacetoacetate hydrolase by stratified nanoplatforms orchestrates metabolic-immune reprogramming and prevents post-ablation HCC relapse.
Journal: Nature communications
Published: November 25, 2025
miR-200a-3p promotes the malignancy of endometrial carcinoma through negative regulation of epithelial-mesenchymal transition.
Journal: Discover oncology
Published: February 12, 2024
PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: June 11, 2023
Corrigendum: A potential indicator ARRDC2 has feasibility to evaluate prognosis and immune microenvironment in ovarian cancer.
Journal: Frontiers in genetics
Published: June 26, 2022
ATAD2 Upregulation Promotes Tumor Growth and Angiogenesis in Endometrial Cancer and Is Associated with Its Immune Infiltration.
Journal: Disease markers
Published: June 20, 2022
KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Journal: Molecular omics
Published: April 29, 2022
A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer.
Journal: Frontiers in genetics
Published: November 15, 2021
UBE2T regulates epithelial-mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer.
Journal: Journal of ovarian research
Published: October 03, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026